Cell Signaling Modulation — Enzo Therapeutics
Cell Signaling Modulation
Targeting key signaling pathways with precision small molecules. Our FLUOR DE LYS® epigenetic platform and SCREEN-WELL® compound libraries drive discovery of novel therapeutics for oncology, neurodegeneration, and inflammatory diseases.
Proprietary Platforms for Small Molecule Drug Discovery
Enzo’s cell signaling modulation platform integrates two industry-leading technologies: the FLUOR DE LYS fluorometric assay platform — the gold standard for measuring histone deacetylase and sirtuin enzyme activities — and our curated SCREEN-WELL compound libraries containing thousands of annotated bioactive molecules. Together, these platforms enable the systematic discovery of novel signaling modulators with differentiated mechanisms of action for therapeutic development.
FLUOR DE LYS® Epigenetic Modulators
The FLUOR DE LYS platform is the gold standard for HDAC and sirtuin drug discovery. Widely adopted by the pharmaceutical industry, it has enabled identification of novel HDAC inhibitors now in clinical trials. Enzo is leveraging this platform expertise to develop proprietary epigenetic modulators with improved isoform selectivity and therapeutic indices for oncology and neurodegenerative indications.
SCREEN-WELL® Kinase Inhibitors
Curated kinase inhibitor libraries covering major kinase families for targeted oncology and inflammatory signaling pathway intervention. SCREEN-WELL collections include selective and multi-targeted inhibitors with detailed mechanism-of-action annotations, enabling rapid identification of clinical candidates from phenotypic and biochemical screens.
Apoptosis & Autophagy Modulators
Small molecule modulators of programmed cell death pathways including pro-apoptotic agents for cancer therapy and cytoprotective compounds for neurodegeneration. Our SCREEN-WELL Apoptosis and Autophagy libraries provide annotated compound collections for modulating Bcl-2 family proteins, caspases, and autophagic flux regulators.
Integrated Screening Platform
End-to-end drug discovery capability combining SCREEN-WELL compound libraries (3,000+ annotated bioactive molecules), FLUOR DE LYS enzymatic assays, and cell-based phenotypic screening tools. Our FDA-Approved Drug Library enables rapid repurposing screens for novel therapeutic indications with known safety profiles.
Cell Signaling Modulation — By the Numbers
Discover Novel Signaling Modulators
Connect with our business development team to explore licensing, co-development, and technology transfer opportunities across our therapeutic platforms.